[{"orgOrder":0,"company":"Chengdu Zenitar Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Flonoltinib Maleate","moa":"CDK6\/FLT3\/JAK2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Chengdu Zenitar Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chengdu Zenitar Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Chengdu Zenitar Biomedical Technology \/ Undisclosed"},{"orgOrder":0,"company":"Chengdu Zenitar Biomedical Technology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Miscellaneous","year":"2026","type":"Inapplicable","leadProduct":"Flonoltinib maleate","moa":"CDK6\/FLT3\/JAK2","graph1":"Oncology","graph2":"Phase III","graph3":"Chengdu Zenitar Biomedical Technology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Chengdu Zenitar Biomedical Technology \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Chengdu Zenitar Biomedical Technology \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for Flonoltinib maleate

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IPPE
                          Not Confirmed
                          IPPE
                          Not Confirmed

                          Details : Flonoltinib Maleate is a Miscellaneous drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Primary Myelofibrosis.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          January 05, 2026

                          Lead Product(s) : Flonoltinib maleate

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Chengdu Zenitar Biomedical Technology

                          Country arrow
                          IPPE
                          Not Confirmed

                          Chengdu Zenitar Biomedical Technology

                          Country arrow
                          IPPE
                          Not Confirmed

                          Details : Flonoltinib Maleate is a Small Molecule drug candidate drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 26, 2025

                          Lead Product(s) : Flonoltinib maleate

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank